After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead.
NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company's target indication represents a multi-billion-dollar market with no FDA-approved therapy; consequently, there are many other NASH-focused biotechs, most of which are later-stage. NASH biotechs as a whole have not done well, save for June IPO Akero Therapeutics ([[AKRO]]; +28% from IPO). A holdover from last week, the company delayed its offering due to a minor issue with